High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
Status:
Active, not recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy
can help to control germ-cell tumors. The first cycle of chemotherapy will include the drugs
gemcitabine, docetaxel, melphalan, and carboplatin. The second cycle of chemotherapy will
include the drugs ifosfamide, carboplatin, and etoposide. The safety of these drug
combinations will also be studied.
This is an investigational study. Gemcitabine, docetaxel, melphalan, ifosfamide, carboplatin,
and etoposide are all FDA-approved and commercially available for the treatment of germ-cell
tumors.
Up to 67 patients will be enrolled in this study.